Cargando…
Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure
BACKGROUND: We investigated the clinical significance of derivatives of reactive oxygen metabolites (DROMs), a new marker of reactive oxygen species, in patients with nonischemic heart failure (HF) and compared them among new categories of HF. METHODS AND RESULTS: We recruited 201 consecutively hosp...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174381/ https://www.ncbi.nlm.nih.gov/pubmed/33733816 http://dx.doi.org/10.1161/JAHA.120.016765 |
_version_ | 1783702899145048064 |
---|---|
author | Nishihara, Taiki Yamamoto, Eiichiro Sueta, Daisuke Fujisue, Koichiro Usuku, Hiroki Oike, Fumi Takae, Masafumi Tabata, Noriaki Ito, Miwa Yamanaga, Kenshi Kanazawa, Hisanori Arima, Yuichiro Araki, Satoshi Takashio, Seiji Nakamura, Taishi Suzuki, Satoru Sakamoto, Kenji Izumiya, Yasuhiro Kaikita, Koichi Tsujita, Kenichi |
author_facet | Nishihara, Taiki Yamamoto, Eiichiro Sueta, Daisuke Fujisue, Koichiro Usuku, Hiroki Oike, Fumi Takae, Masafumi Tabata, Noriaki Ito, Miwa Yamanaga, Kenshi Kanazawa, Hisanori Arima, Yuichiro Araki, Satoshi Takashio, Seiji Nakamura, Taishi Suzuki, Satoru Sakamoto, Kenji Izumiya, Yasuhiro Kaikita, Koichi Tsujita, Kenichi |
author_sort | Nishihara, Taiki |
collection | PubMed |
description | BACKGROUND: We investigated the clinical significance of derivatives of reactive oxygen metabolites (DROMs), a new marker of reactive oxygen species, in patients with nonischemic heart failure (HF) and compared them among new categories of HF. METHODS AND RESULTS: We recruited 201 consecutively hospitalized patients with HF and measured DROM under stable conditions. Then, we divided them according to new categories of HF (HF with reduced ejection fraction [EF], HF with midrangeEF, and HF with preserved EF) without coronary artery disease. In subgroup analysis, we followed EF changes in patients with HF with reduced EF and classified them into HF with recovered EF or nonrecovered EF according to whether EF had improved to >40%. DROMs are significantly and independently associated with HF‐related events in patients with NIHF. There were no significant differences in DROM and the probability of HF‐related events among HF categories in Kaplan–Meier analysis. However, patients with HF with reduced EF and HF with preserved EF but not HF with midrange EF with HF‐related events had higher DROM than those without HF‐related events. In subgroup analysis, Kaplan–Meier analysis demonstrated that the probabilities of HF‐related events in HF with recovered EF were dramatically decreased. DROM were significantly higher in patients with HF with nonrecovered EF than in HF with recovered EF. In receiver operating characteristic analysis, the cutoff level of DROM for predicting improvements in HF with recovered EF was 347 Carratelli units. Furthermore, the C‐statistic value for predicting EF improvement for the DROM levels was 0.703. In multivariable logistic regression analysis, DROM was independently and significantly associated with the prediction of HF with recovered EF. CONCLUSIONS: DROM measurements can provide important prognostic information for risk stratification in any category of NIHF. REGISTRATION: URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000035827. |
format | Online Article Text |
id | pubmed-8174381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81743812021-06-11 Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure Nishihara, Taiki Yamamoto, Eiichiro Sueta, Daisuke Fujisue, Koichiro Usuku, Hiroki Oike, Fumi Takae, Masafumi Tabata, Noriaki Ito, Miwa Yamanaga, Kenshi Kanazawa, Hisanori Arima, Yuichiro Araki, Satoshi Takashio, Seiji Nakamura, Taishi Suzuki, Satoru Sakamoto, Kenji Izumiya, Yasuhiro Kaikita, Koichi Tsujita, Kenichi J Am Heart Assoc Original Research BACKGROUND: We investigated the clinical significance of derivatives of reactive oxygen metabolites (DROMs), a new marker of reactive oxygen species, in patients with nonischemic heart failure (HF) and compared them among new categories of HF. METHODS AND RESULTS: We recruited 201 consecutively hospitalized patients with HF and measured DROM under stable conditions. Then, we divided them according to new categories of HF (HF with reduced ejection fraction [EF], HF with midrangeEF, and HF with preserved EF) without coronary artery disease. In subgroup analysis, we followed EF changes in patients with HF with reduced EF and classified them into HF with recovered EF or nonrecovered EF according to whether EF had improved to >40%. DROMs are significantly and independently associated with HF‐related events in patients with NIHF. There were no significant differences in DROM and the probability of HF‐related events among HF categories in Kaplan–Meier analysis. However, patients with HF with reduced EF and HF with preserved EF but not HF with midrange EF with HF‐related events had higher DROM than those without HF‐related events. In subgroup analysis, Kaplan–Meier analysis demonstrated that the probabilities of HF‐related events in HF with recovered EF were dramatically decreased. DROM were significantly higher in patients with HF with nonrecovered EF than in HF with recovered EF. In receiver operating characteristic analysis, the cutoff level of DROM for predicting improvements in HF with recovered EF was 347 Carratelli units. Furthermore, the C‐statistic value for predicting EF improvement for the DROM levels was 0.703. In multivariable logistic regression analysis, DROM was independently and significantly associated with the prediction of HF with recovered EF. CONCLUSIONS: DROM measurements can provide important prognostic information for risk stratification in any category of NIHF. REGISTRATION: URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000035827. John Wiley and Sons Inc. 2021-03-18 /pmc/articles/PMC8174381/ /pubmed/33733816 http://dx.doi.org/10.1161/JAHA.120.016765 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Nishihara, Taiki Yamamoto, Eiichiro Sueta, Daisuke Fujisue, Koichiro Usuku, Hiroki Oike, Fumi Takae, Masafumi Tabata, Noriaki Ito, Miwa Yamanaga, Kenshi Kanazawa, Hisanori Arima, Yuichiro Araki, Satoshi Takashio, Seiji Nakamura, Taishi Suzuki, Satoru Sakamoto, Kenji Izumiya, Yasuhiro Kaikita, Koichi Tsujita, Kenichi Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title | Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title_full | Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title_fullStr | Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title_full_unstemmed | Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title_short | Impact of Reactive Oxidative Metabolites Among New Categories of Nonischemic Heart Failure |
title_sort | impact of reactive oxidative metabolites among new categories of nonischemic heart failure |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174381/ https://www.ncbi.nlm.nih.gov/pubmed/33733816 http://dx.doi.org/10.1161/JAHA.120.016765 |
work_keys_str_mv | AT nishiharataiki impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT yamamotoeiichiro impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT suetadaisuke impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT fujisuekoichiro impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT usukuhiroki impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT oikefumi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT takaemasafumi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT tabatanoriaki impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT itomiwa impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT yamanagakenshi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT kanazawahisanori impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT arimayuichiro impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT arakisatoshi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT takashioseiji impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT nakamurataishi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT suzukisatoru impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT sakamotokenji impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT izumiyayasuhiro impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT kaikitakoichi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure AT tsujitakenichi impactofreactiveoxidativemetabolitesamongnewcategoriesofnonischemicheartfailure |